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EFFECT OF ARYL-HYDROCARBON RECEPTOR ACTIVITY ON LIPID 
ACCUMULATION, INSULIN CONTENT AND SECRETION FROM CLONAL 
PANCREATIC BETA-CELLS  
??SIYOUNEH BAGHDASARIAN  
ABSTRACT 
Objective. The aryl hydrocarbon receptor (AhR) translocates to the nucleus and 
binds to the aryl hydrocarbon receptor nuclear translocator (ARNT) to regulate biological 
responses upon ligand activation. The aim of this study was to measure the effects of 
activation or inhibition of AhR activity on basal and glucose-stimulated insulin secretion 
(GSIS) from clonal pancreatic b-cells (INS-1) cultured under normal and glucolipotoxic 
(GLT) conditions (high glucose and fatty acid). 
Methods. Insulin content and secretion were measured utilizing homogenous time-
resolved fluorescence (HTRF) insulin assay kit (cisbio). Cells cultured in RPMI media 
containing 5 mM and 11 mM glucose were pre-incubated with the receptor agonist FICZ 
or antagonist CH223191 for 96 hours. Insulin secretion over 2 hours was reported as 
ng/million cells. Intracellular lipid was measured by fluorescence after Nile red staining. 
Results. Incubation of INS-1 cells with 11 mM glucose and fatty acid increased 
lipid droplets, basal insulin secretion and inhibited GSIS compared to cells cultured in 4 
mM glucose, characteristic of GLT. Incubation of INS-1 cells with 11 mM glucose alone 
also exhibited GLT characteristics.  INS-1 cells cultured at 11 mM glucose and treated with 
antagonist (1.25 - 10 µM) had decreased lipid content and improved insulin secretion 
compared to cells cultured in 11 mM glucose alone. INS-1 cells cultured in 5 mM glucose 
  viii 
and treated with the AhR agonist (1.25 - 10 µM) exhibited increased intracellular lipid and 
impaired insulin secretion.  
Conclusion. The AhR may play a mediatory role in the development of GLT in 
pancreatic b-cells cultured in excess nutrients and b-cell specific activator or inhibitor 
ligands of this receptor could potentially be a targeted therapeutic treatment of diabetes.   
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 1 
INTRODUCTION 
 
 The prevalence of diabetes is growing in the United States and worldwide. It is 
predicted by the International Diabetes Federation (IDF) that the number of people of 
working age with diabetes worldwide is going to increase to 438 million in 2045  (“IDF 
Diabetes 2017 Atlas”). According to the latest CDC report, in the United States an 
estimated 30.3 million people of all ages were reported to have diabetes in 2015.  30.2 
million people (12.2% of US adults) 18 and older have diabetes, of which 7.2 million 
(23.8%) are undiagnosed (CDC 2017 report).  From the two major types of diabetes; type 
1 and 2 (T1D, T2D), at least 90% of T2D is associated with concurrent obesity (WHO).  
People with obesity are at greater risk for T2D, than people with lower BMI, and 
obesity is known to be a major independent risk factor for developing T2D (Obesity 
society). According to national health and nutrition examination survey (NHANES) report 
of 2013-2014 more than 1 in 3 adults are considered to be overweight or obese  (Flegal et 
al. 2016). 
It is therefore proper to ask why there is a big outbreak in obesity now more than 
before? The Downy obesity report, has recently stated that there are more than 100 causes 
of obesity.  Among the causes listed, environmental factors stand out in that they contribute 
a major part in the obesity epidemic. Among these environmental factors, environmental 
toxins and pollutants have been the focus of scientists and have been intensively studied. 
Some interesting results obtained from these studies show that air pollution is linked to 
childhood obesity due to maternal exposure to polycyclic aromatic hydrocarbons (AhR) 
during pregnancy (Rundle et al. 2012). A study using 3T3-L1 adipocytes suggests that the 
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activated AhR may be a participant in the fat metabolism and therefore contributes to the 
development of obesity (Arsenescu et al. 2008).  
AhR is a well-studied ligand-activated nuclear receptor that has major 
transcriptional activity in the nucleus. It is known for its ability to regulate toxicant 
metabolism providing a protective effect, in addition to its biological and developmental 
regulation of metabolic pathways (Fernandez-Salguero et al. 1995).  
It is well known that excess nutrient intake, frequently attributed to increased 
availability of food supplies is associated with urbanization and decreased activity, which 
is thought to play a major role in the obesity epidemic (Popkin 2006; Misra and Khurana 
2008). In recent years there is additional evidence to suggest that with urbanization, 
chemicals and toxins were introduced into our daily life that are known to be major 
endocrine disruptors. These environmental toxins stimulate overconsumption of food and 
contribute to the obesity epidemic (Kerley-Hamilton et al. 2012; Karoutsou and Polymeris 
2012).  
Despite the growing prevalence of obesity and diabetes, the role of b-cell function 
in the pathogenesis of T2D is not completely understood.  The focus of this thesis is to 
investigate the potential role of the aryl hydrocarbon receptor in the pathogenesis of T2D. 
Does a high fat and glucose diet (excess nutrient condition) stimulate activity of the AhR 
and lead to pancreatic b-cell dysfunction over time? Does activation of the AhR exacerbate 
the effects of excess nutrients to impair ß-cell function? 
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B-cell function, insulin secretion, and insulin resistance 
Despite years of research, the respective roles of insulin hypersecretion, insulin 
resistance, and pancreatic b-cell function in the origins of T2D are controversial. Pancreatic 
b-cells are sensitive to glucose concentration and are known to synthesize and secrete 
insulin to maintain blood glucose levels within a narrow physiological range of 4.4 to 6.1 
mmol/L (79.2 to 110 mg/dl) as measured by fasting blood glucose. Impairment in normal 
secretion of insulin by pancreatic b-cells or impaired insulin action as in insulin resistance 
can lead to hyperglycemia and a diagnoses of T2D (Barbara E. Corkey 2012; ADA 2015, 
2009). T2D is characterized by ≥126 mg/dL (7 mmol/L) fasting glucose in the blood, which 
could be caused, by not only a lack of insulin but also the inability of insulin to efficiently 
lower glucose in the blood.  
Pathway of insulin secretion in b-cells 
 The mechanisms involved in the fusion of insulin granules to the b-cell membrane 
and subsequent exocytosis are known to involve both triggering and amplification 
pathways (Henquin 2000). In the triggering pathway of insulin secretion (Figure 1), 
glucose is transported into the cell by GLUT-2 and phosphorylated by glucokinase (GK), 
described as the glucose sensor (Davis et al. 1999). Once inside the cell, glucose is 
metabolized through glycolytic and mitochondrial fuel oxidative pathways to produce 
ATP. The ATP-sensitive K+ channel (KATP) located at the b-cell plasma membrane is 
sensitive to the cytosolic ATP/ADP ratio inside the cell, and when this ratio increases the 
KATP channel closes and leads to membrane depolarization and opening of voltage-gated 
Ca2+ channels. Upon opening of Ca2+ channels, Ca2+ levels increase inside the cell and 
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stimulate fusion of insulin granules to the plasma membrane and insulin exocytosis (Figure 
1). The glucose induced insulin secretion is well known to be oscillatory due to the 
oscillations both in the ATP/ADP ratio and cytoplasmic free Ca2+ concentration (M. Prentki 
and Corkey 1996). The metabolism of glucose to stimulate insulin secretion is oscillatory 
and therefore resulting secretion is also oscillatory (Deeney et al. 2001) 
This oscillatory behavior benefits insulin sensitive targeted tissues by 1) preventing 
down regulation of insulin receptor and as a result 2) provides for more efferent glucose 
removal from the blood (Sturis et al. 1991; Polonsky et al. 1988; Meglasson Martin D. and 
Matschinsky Franz M. 2009). 
 
 
 5 
 
Figure 1: Triggering pathway of insulin secretion in pancreatic b-cells. 
Upon glucose entry into the cell and production of ATP through mitochondrial fuel oxidation, the 
ATP/ADP ratio rises. A high ATP/ADP ratio closes the KATP channel and results in depolarization 
of the plasma membrane. A depolarized membrane triggers opening of voltage dependent calcium 
channels and Ca2+ entry. A rise in the Ca2+ concentration inside the cell triggers insulin vesicles to 
attach to membrane and promotes exocytosis.  
 
 
In the amplification pathway (Figure 2), glucose-induced insulin secretion is further 
increased above and beyond just the effect of the increased Ca2+ concentration. The signals 
involved in this amplification are hypothesized to include other glucose metabolites, free 
fatty acids or the activated FA-CoA esters and cyclic AMP (cAMP). It is known that long-
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chain fatty acids (LCFAs) amplify and in fact are required for normal glucose-stimulated 
insulin secretion (GSIS) (Nolan et al. 2006; Latour et al. 2007). LCFAs enter the cell via a 
flip-flop mechanism (Kamp et al. 2003; Hamilton 1998). FA can also come from direct 
activity of lipases on TG, DG or MG inside the cell (Berdan et al. 2016; Labar, Wouters, 
and Lambert 2010; Mulvihill and Nomura 2013). Once fatty acids enter the cell, they are 
converted to long-chain fatty acyl-coenzyme A esters (LC-CoA) to be further metabolized.  
b-cells normally use FA as a fuel when glucose concentrations are low, as in 
between meals.  When glucose is elevated and metabolized, malonyl-CoA, an inhibitor of 
CPT1, is formed from glucose and increases in the cytosol to inhibit LC-CoA oxidation 
(McGarry et al. 1989; Civelek et al. 1996). LC-CoA when spared from oxidation can be 
incorporated into lipids and proteins to potentially enhance secretion (Roduit et al. 2004; 
Nolan et al. 2006). This has been described as the LC-CoA hypothesis in the b-cell (M. 
Prentki and Corkey 1996). In addition, LC-CoA itself (Deeney et al. 2000; Larsson et al. 
1996) or via protein kinase C (PKC) activity (Corkey et al. 2000) that can also drive insulin 
granule exocytosis. The triggering and amplification pathways of insulin secretion 
mentioned above are important in normal b-cell function and are disrupted in diabetic 
patients.  
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Figure 2: Amplification pathway of insulin secretion in pancreatic b-cells. 
In addition to the triggering pathway, there are other metabolites such as LC-CoA that are 
responsible for further exocytosis of insulin granules. LC-CoA directly or indirectly via PKC 
involvement is responsible for exocytosis of insulin granules shown above.  
 
 
Insulin resistance  
There are two phenomena that have been proposed to potentially lead to 
hyperinsulinemia. The first and long-held view postulates that accumulation of lipid in 
peripheral tissues, specifically, muscle, white adipose tissue, and liver, leads to insulin 
resistance and hyperglycemia (Marc Prentki and Nolan 2006). The b-cell then secretes 
more insulin in response to elevated glucose, exacerbating the insulin resistance. A more 
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recent, less-accepted view is that accumulation of lipid in the pancreatic b-cell drives 
increased insulin secretion at low glucose and the subsequent hyperinsulinemia results in 
insulin resistance in peripheral tissues (Shanik et al. 2008; Barbara E. Corkey 2012). 
It is not clear as to why b-cells hypersecrete insulin under fasting conditions and so 
to better understand the pathogenesis of b-cells under excess nutrient condition (which 
mimics Western diet), we decided to study the role of AhR in the b-cell and determine its 
role if any in the pathogenesis of b-cell dysfunction.   
Aryl hydrocarbon receptor signaling pathway 
The AhR is a ligand activated transcription factor well known to be activated by 
environmental contaminants such as dioxin (TCDD, 2, 3,7,8-tetrachlorodibenzo-p-dioxin) 
(Beischlag et al. 2008). TCDD is a trace byproduct formed in the synthesis of phenoxy 
herbicide 2,4,5-trichlorophenoxyacetic acids and chlorophenol (Assessment 2009; Y.-H. 
Kim et al. 2009). Lipophilic molecules including polycyclic or halogenated aromatic 
hydrocarbons are the best-known AhR ligands (Soshilov and Denison 2014).  AhR also 
binds natural ligands from plants such as flavonoids, polyphenolics and indoles (Mulero-
Navarro and Fernandez-Salguero 2016). AhR is also activated by dietary compounds 
including fats and fat derivatives (McMillan and Bradfield 2007; Tanos et al. 2012). AhR 
is also known to be activated by short chain fatty acids (SCFA); butyrate, propionate and 
acetate (Jin et al. 2017).  
In the absence of the ligand, AhR is located in the cytoplasm bound to a molecular 
chaperon complex (Hsp90/XAP2/p23) (Figure 3). Upon ligand binding of this receptor, the 
receptor translocates into the nucleus and heterodimerizes with the aryl hydrocarbon 
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nuclear translocator (ARNT). The heterodimer binds to a co-activator or a co-repressor and 
interacts with consensus regulatory sequences xenobiotic response elements 
(XREs)/dioxin response elements (DREs) in the promoter region of many targeted genes 
including cytochrome p450 (CYP1A1, CYP1A2, CYP1B1), Interleukin’s (IL 17 and 22) 
and others (Figure 3) (Zhou 2016; Beischlag et al. 2008). Once transcription has occurred, 
the AhR dissociates from DNA and translocates back into the cytoplasm where it is 
degraded by the proteasome. One of the many target genes of AhR is the AhR repressor 
(AhRR) which acts as a potential inhibitor and binds to ARNT and sequesters ARNT in 
the form of AhRR-ARNT, therefore inhibiting its normal translational activity (Beischlag 
et al. 2008). This diagram below illustrates what is known to be AhR activation and 
signaling pathway (redrawn from trends in immunology) (Zhou 2016). 
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Figure 3: AhR receptor activation and signaling pathway. 
In the presence of the agonist ligand (gray tri-octagon), the receptor (pink diamond) in the 
cytoplasm, along with a chaperone protein (blue square, violet circle, coral oval) bond to it 
translocates into the nucleus. After localization in the nucleus, the chaperones dissociate from the 
receptor and the receptor therefore is able to bind to its partner ARNT (purple diamond). Upon 
binding of AhR to ARNT, the complex acts as a transcription factor and binds to its response 
element (AhRE) and activates transcription of downstream transcripts. After the transcription has 
occurred, the AhR dissociates from DNA and translocates back into the cytoplasm where it 
is degraded (pink small pieces of diamonds) by the proteasomes.  
 
 
Epidemiological studies of AhR 
Association studies have been conducted to better understand the TCDD effect in 
industrial workers. Most studied were Air Force veterans who were in charge of spraying 
Agent Orange in Vietnam and exhibited greater prevalence of diabetes (Henriksen et al. 
1997). TCDD has been shown to impair carbohydrate metabolism (Henriksen et al. 1997; 
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Pazderova-Vejlupková et al. 1981) induce hepatic steatosis and result in an abnormal 
glucose tolerance test. Increased mean TCDD level was also found in diabetic workers 
(Pazderova-Vejlupková et al. 1981). TCDD is well known to be associated with 
hyperinsulinemia and insulin resistance (Cranmer et al. 2000). In addition, in a longitudinal 
study by NHANES both total urinary polycyclic aromatic hydrocarbon (PAH) metabolites 
and naphthalene metabolites were found to be associated with higher BMI, waist 
circumference and obesity in children 6-11 years of age (Scinicariello and Buser 2013).  
Animal studies: knock out and knock in studies that demonstrate the importance of 
AhR and its activity 
The importance of the AhR receptor and its signaling is better understood as a result 
of many laboratory experiments. AhR activity has been documented in many organs and 
tissues in the body (Pohjanvirta and Tuomisto 1994). It has been shown that AhR is 
involved in triglyceride synthesis in adipose tissue and liver. In addition in the inhibition 
of adiposeness peroxisomal proliferator-activated receptor gamma (PPARg) is known to 
be involved(Alexander et al. 1998; Ernst et al. 2014; Vieweg et al. 2018; Gdula-Argasińska 
et al. 2016). 
Over-expression of AhR has been shown to promote obesity, hepatic fatty liver 
diseases and insulin resistance (Xu et al. 2015). AhR deficiency has been shown to improve 
high fat diet induced insulin resistance, hyperglycemia and hyperinsulinemia (Xu et al. 
2015). Glucose-stimulated insulin secretion from islets isolated from mice that were 
pretreated for 24 hours with an AhR agonist was significantly decreased. However, insulin 
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secretion from isolated islets treated with agonist for 24 hours was not different from 
controls (Kurita et al. 2009).   
Intracellular calcium was increased after acute AhR agonist exposure in INS-1 cells 
(Y.-H. Kim et al. 2009). ARNT knock down with siRNA results in decreased expression 
of the KATP channel subunit Kir6.2, leading to decreased basal and GSIS (J.-S. Kim et al. 
2009).  
Glucolipotoxicity and excess nutrients  
In order to mimic the in-vivo microenvironment of the b-cell under excess nutrient 
conditions, clonal pancreatic b-cells (INS-1) are cultured in-vitro at high glucose (11 mM 
glucose) with the lipid present in 10% FBS (TG and FFA). Our lab’s previous date shows 
that excess nutrients (high glucose and fatty acid) induce glucolipotoxicity (GLT) 
characterized by increased basal and decreased glucose-stimulated insulin secretion (GSIS) 
in clonal pancreatic b-cells (Saadeh et al. 2012). Additionally, under GLT conditions, cells 
accumulate intracellular lipid droplets and GSIS is left-shifted as a result (Figure 4) 
(redrawn from Erion et al. 2015). It is proposed that this is a way that excess nutrients lead 
to an increase in insulin secretion at low glucose, also known as basal hyperinsulinemia 
under fasting conditions, which can lead to obesity (Corkey 2012). 
It is not clear how b-cells accumulate lipids and what metabolic parameters change 
as a consequence. We have yet to understand how normal functioning b-cells acquire such 
characteristics after they are exposed to the high glucose and fatty acid environment. The 
accumulation of cytosolic lipid droplets suggests lipid metabolism is altered and that this 
may play a role in the dysfunction of b-cells. Since the AhR has been shown to affect both 
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lipid and carbohydrate metabolism, we investigated the effects of this receptor on lipid 
accumulation and insulin secretion from clonal b-cells.  
We aimed to measure the effect of AhR activity on lipid accumulation and insulin 
secretion from clonal pancreatic b-cells exposed to excess nutrients. We hypothesize that 
due to the nature of the AhR ligands, lipophilic molecules found in FBS and delivered as 
a source of nutrients could potentially activate this receptor and impair b-cell function. The 
goal of this study was to determine 1) whether the effect of excess nutrients to induce GLT 
and impair insulin secretion was mediated by the AhR and 2) whether AhR activation 
exacerbates the effects of lipid to impair b-cell function. We investigated this by measuring 
the effects of inhibition (goal 1) or activation (goal 2) of AhR on lipid accumulation, basal 
insulin secretion and GSIS from rat clonal pancreatic b-cells (INS-1) cultured under normal 
and GLT conditions (high glucose and FA). 
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Figure 4: Insulin secretion by INS-1 cells is affected by lipid content in the cells. 
Lipid stores and insulin secretion in INS-1 cells grown 48 hours in the presence of different 
nutrients: 1, 4 mM glucose chronic (n = 12); 2, 4 mM glucose (48 hours) (n = 8); 3, 4 mM 
glucose + 0.15 mM oleate (n = 6); 4, 11 mM glucose chronic culture (n = 13); 5, 11 mM glucose 
+ 0.15 mM oleate (n = 4). Data redrawn from (Erion et al. 2015). 
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MATERIALS AND METHODS  
 
INS-1 cell culture 
Clonal pancreatic β-cells (INS-1 832/13) (Hohmeier et al. 2000) were grown in 4-5 mM 
or 11 mM glucose in Roswell Park Memorial Institute (RPMI 1640) media containing 10 
mM 4-(2-HydroxyEthyl)-1-PiperazineEthaneSulfonic acid (HEPES), 1 mM pyruvic acid, 
50 µM β-mercaptoethanol (BME), 2 mM glutamine, 10 % Fetal Bovine Serum (FBS), 50 
IU/ml penicillin and 50 µg/ml streptomycin. Cells were split once a week to carry the cell 
line and to grow cells in multi-well plates for experiments. Cells were plated in 96 or 48-
well plates (Corning, Corning, NY) to reach the following cell densities on the day 
secretion was tested; 100,000 cells/well for a 96-well plate and 240,000 cells/well in a 
48-well plate. The cell number seeded in these wells was based on the time in culture and 
the doubling time of the INS-1 cells in the different glucose media. The doubling time for 
these cells was 32 hours in 11 mM glucose media and 58 hours in 5 mM glucose media 
(4 mM glucose was also plated using 52-58 hours of doubling time). 
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Figure 5. Experimental timeline of pretreatment of INS-1 cells with high.  
 
 
Insulin secretion  
After specific treatment (addition of fatty acid oleate  (Sigma, St. Louis, MO)  or  AhR 
agonist or antagonist) or glucose change, cells were incubated for 2 hours in 2 mM glucose 
(2G) RPMI (containing 10 mM 4-(2-HydroxyEthyl)-1-PiperazineEthaneSulfonic acid 
(HEPES), 1 mM pyruvic acid) without oleate, agonist or antagonist.   
After 2 hours of incubation in 2G RPMI, cells were pre-incubated for 30 minutes with 2G 
Krebs-Ringer Bicarbonate Buffer (KREBS) containing 119 mM NaCl, 4.6 mM KCL, 5 
mM NaHCO3, 2 mM CaCl2,1 mM MgSO4, 0.15 mM NaHPO4, 0.4 mM KH2PO4, 20 mM 
HEPES, 0.05% Bovine Serum Albumin (BSA) (Sigma, St. Louis, MO) at pH 7.4, in a 
water bath at 37°C. After 30 minutes pre-incubation, cells was placed on ice for 10 minutes 
to lower their temperature. After 10 minutes on ice, the 2G Krebs was removed from the 
cells and cold solutions of 2G, 4G, or 8G KREBS (also known as test solutions) were added 
to the cells immediately on ice.  
These cells were then incubated for additional 2 hours in a 37°C water bath, followed by 
another 10 min incubation on ice.  Secreted insulin in the media were diluted 1:1 in 1% 
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BSA KREBS and centrifuged for 4 minutes 1000 X at 4°C to separate any residue or cells 
transferred throughout the dilution and transfer process. Secreted insulin and content were 
either stored at -80°C or were measured with the HTFR assay kit from Cisbio, and 
fluorescence was measured using the Tecan Infinite M 1000 PRO spectrophotometer 
(fluorescence intensity at; excitation/emission 317/620 nm with bandwidth 20/10nm, gain 
180, flashes on mode2 [100HZ]:50 and z-position of 24000 µm). After reading the Tecan 
these samples were compared to insulin for change in secretion pattern. Insulin secretion 
was standardized based on a standard curve, volume of the test solution used and cell 
number per well. In each experiment and for every condition insulin secretion was 
measured either at 2, 4 and 8G or 2 and 4G in triplicate or quadruplicate and averaged.  
Insulin content extraction and measurement  
Before insulin secretion experiment, two wells from each experimental condition 
were used to extract the cells out of it. When cells were plated in 96-well plates, 150 µl or 
in 48-well plates 500 µl 0.05% trypsin was added to these empty wells (no media 
containing wells).  After the cells rounded up (in about 2 minutes) and lifted from the plate, 
the added trypsin in each well was used to dilute and mix the cells and collected in a 1.5ml 
Eppendorf tube. Trypsin containing cells from two wells was combined in 1.5 ml 
Eppendorf tube and placed on ice (to deactivate the activity of trypsin).  After the collection 
of INS-1 cells into the Eppendorf tube, 11 µl of the experimental and control condition 
sample was placed on hemocytometer to measure the cell density. The cell count obtained 
here was calculated and adjusted for per ml and per well. The rest of the extracted cells 
were centrifuged at 3.4 g for 4 minutes to collect the pellet and was lysed in cold 1XPBS 
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containing 0.1% Triton X-100 (Sigma, St. Louis, MO) and 25 mM NaOH. The lysing of 
INS-1 cells were for the purpose of extracting insulin content (insulin in the cell which is 
not secreted), 
The cell lysate was then diluted 1:1 in KREBS containing 1% BSA and was either stored 
at -80°C or were assayed right away.  The insulin content was also assayed using the 
Homogenous Time-Resolved Fluorescence (HTRF) Insulin assay kit (Cisbio) and 
measured using the Tecan.   
Nile red staining 
For the purpose of staining intracellular lipid droplets in INS-1 cells, Nile red was  
used. 1 mg of Nile red (Sigma, St. Louis, MO) was added to 1 ml sterile dimethyl sulfoxide 
(DMSO) (Sigma, St. Louis, MO). This Nile red stock solution was further diluted 1:1000 
in 2G RPMI (mentioned above). The diluted Nile red was then added to at least one 
designated experimental and control wells (150  µl per well for 96-well plates or 500 µl 
per well for 48-well plates).  After the addition of diluted Nile red solution to the wells, 
cells were incubated for 15 minutes, and then this solution was removed (gently by the use 
of 200 µl pipet or fine tipped suction). 2G RPMI without Nile red was added to each well, 
then kept in incubator for 5-10 minutes (to let cells rest and settle). A fluorescent image of 
the Nile red-stained cells was taken using a Nikon TE 200 fluorescent microscope 
(Excitation 488nm/Emission 515nm) at 20x magnification after 5-10 minutes equilibration 
of the incubation in the incubator.  
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ImageJ analysis  
ImageJ 1.51m9 version program was obtained from the National Institutes of 
Health, USA (http://imagej.nih.gov/ij). ImageJ was used for the analysis and quantification 
purposes of the Nile red image obtained from the Nikon TE 200 fluorescence  microscope 
as a percentage of the total cell area. To measure the intracellular lipid, the total cell area 
was first measured using specific threshold (threshold at which the majority of the cell area 
is highlighted and covered) then total lipid area was measured using a threshold that would 
include the area in which lipid was visualized. Each image obtained from Nikon T200 was 
first split into three channels via plugins<Bio-Formats<Bio-Formats Importer [plugin add-
in was installed in 1.51m9 version of ImageJ software] and then cropped to reduce the size 
of the image to 600X600 pixels. The background of each image was reduced to 50 pixels. 
After cropping and reducing the background, a duplicate of the cropped image was made 
in order to apply the best threshold (max coverage) to obtain the total cell area and the lipid 
area (each on separate cropped image). At the very last step, the analyze and histogram 
functions of ImageJ were utilized to extract a numerical value for each threshold, which is 
representative of the total cell area and lipid area. For analysis purposes, percent lipid was 
measured in each cell using total lipid and cell area. Data were analyzed looking at percent 
lipid as a function of the cell area. Later for each experimental or glucose conditions cells 
were normalized to their own control. 
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Figure 6. Experimental timeline of pretreatment of INS-1 cells with high glucose and fatty 
acid.  
 
 
Glucolipotoxic INS-1 cell pretreatment  
To mimic the glucolipotoxic effect, cells were grown chronically in media 
containing 4 mM glucose and switched to media containing 11 mM glucose and 0.1 mM 
oleate (Sigma, St. Louis,MO) in DMSO complexed to 10% FBS for 48 hours. Oleate 
dissolved in DMSO was complexed to FBS prior to the day of treatment at 57°C during 
several slow additions followed by immediate vortexing and replacement of the FBS tube 
in 57°C water bath. The purpose of dissolving oleate in FBS was to obtain a clear solution, 
which is indicative of successful complexing of the FBS with fatty acid oleate.  
After the treatment of chronic 4G INS-1 cells with 0.1 mM oleate and increasing the media 
to 11 mM glucose for 48 hours, insulin content and secretion were measured. Additionally, 
intracellular lipid droplet content was also measured using Nile red followed by ImageJ 
analysis.  
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Figure 7. Experimental timeline of pretreatment of INS-1 cells with 5 mM glucose and AhR 
ligands.  
 
 
AhR ligand dose response 
Two days after plating cells cultured in 5 mM glucose, AhR agonist FICZ (Tocris, 
Minneapolis, MN) and the AhR antagonist CH223191(Sigma, St. Louis, MO) using a 10 
mM working solution diluted in DMSO were added to cells at concentrations of 10, 5, 1.25 
and 0 µM and incubated for three days. The compounds at appropriate concentrations were 
changed on the second day of treatment. After three days of incubation, insulin secretion 
experiment was measured. The compounds were not present in the test solutions during 
insulin secretion experiments. 
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Figure 8. Experimental timeline of pretreatment of INS-1 cells with AhR antagonist (top) and 
agonist (bottom).  
 
 
AhR agonist and antagonist ligand incubations 
Two days after plating, cells cultured in either chronic 5 or 11 mM glucose were 
used and was pretreated with the AhR agonist FICZ or the AhR antagonist CH223191 for 
the following four days (96 hours). AhR agonist was added at 10, 1.25 and 0 µM 
concentrations to the cells chronically cultured in 5 mM glucose RPMI.  The agonist was 
added in 5 mM glucose RPMI media in order to maintain the glucose exposure. Percent 
lipid in the cell was measured as a function of the dose of AhR 10, 5, 2.5, 1.25 and 0 µM 
concentrations were used and the glucose concentration was raised to 8 and 11mM. When 
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AhR antagonist was added to cells chronically cultured in 11 mM glucose RPMI, the 
compounds were either added in 11 mM glucose media or in 7 mM glucose RPMI media 
in order to maintain or decrease the glucose exposure, respectively. Percent lipid in the cell 
was measured as the dose of AhR antagonist used were 10, 5, 2.5, 1.25 and 0 µM and 
glucose concentrations were dropped to 8 and 5 mM.  
 The agonist or antagonist treatment continued for 4 days under the new culture 
conditions. The compounds at the appropriate glucose concentrations were changed every 
two days until the day of the experiment. Compounds were not present during the 
incubations for insulin secretion. After four days of incubation of these cells, insulin 
secretion experiments was performed, insulin content was measured, and the insulin was 
measured as described above. Additionally, Nile red staining of these cells was done and 
analyzed as described above. 
Statistical analysis 
  The data are presented as the mean of three to four independent experiment ± 
(standard error of the mean) S.E.M. Statistical significance in each experiment was 
calculated using two-tailed Student’s t-test. Analysis of Covariance (ANOVA) one-way or 
two-ways were also utilized in experiments as indicated in the figure legends. A p-value of 
<0.05 denoted as (*) was considered to be statistically significant. 
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RESULTS 
 
Insulin secretion by INS-1 cells cultured in 5 mM glucose  
 INS-1 cells were cultured in 5 mM glucose for 72 hours to mimic normal 
physiological blood glucose concentrations in were acutely stimulated at increasing 
glucose concentrations of 2, 4, 6, 8 and 12 mM. Insulin secretion over this glucose 
concentration range when plotted resulted in a sigmoidal curve (Figure 9). Insulin secretion 
from these cells when glucose was raised from 2 mM to 4 mM was relatively unchanged 
(30% increase) compared to the 3-fold or 200% increase in secretion when glucose was 
raised from 4 mM to 8 mM. The increase in secretion when glucose was raised from 8 mM 
to 12 mM was equal to only 7%.  Thus, the insulin secretory profile from INS-1 cells 
cultured under low glucose conditions includes basal insulin secretion at 2-4 mM glucose, 
stimulated insulin secretion induced by glucose concentrations between 4 and 8 mM and 
maximal secretion levels achieved at 8 mM glucose and above.  
 The absolute values for insulin release from INS-1 cells cultured at 5 mM glucose 
as shown in Figure 9 are 28 ng/106 cells and 112 ng/106 cells at 2 mM and 8 mM glucose, 
respectively. It is important to note that these values fluctuate and are not exactly the same 
among experiments. Basal insulin secretion measured at 2 mM glucose in our studies 
ranged from 5-29 ng/106 cells.  Stimulated insulin secretion also varies and was in the range 
of 23 to 112 ng/106 cells resulting in a 3- to 9-fold stimulation from basal to maximal 
secretion (2 to 8 mM glucose) in all experiments. A built-in quality control in our 
experiments was the expectation that stimulation from healthy cells would be at least 3-
 25 
fold. Experiments that did not meet this standard were not considered appropriate to be 
included in results. 
 
 
 
 
Figure 9. GSIS from INS-1 cells cultured at low glucose.  
INS-1 cells were cultured in 5mM glucose for 72 hours and stimulated at increasing glucose 
concentrations (from 2-12 mM).  Insulin secretion increased 3-fold between 4 mM and 8 mM 
glucose, while it was relatively unchanged below 4 mM glucose (basal secretion) or higher than 8 
mM glucose (maximal secretion). Similar results were obtained in four other such experiments 
and the graph above represents an independent experiment with three to four replicates averaged 
and plotted as a mean ± S.E.M. 
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Insulin secretion by INS-1 cells cultured with excess nutrients 
 We were then interested to measure insulin secretion from INS-1 cells after 
exposure to excess nutrients (high glucose and fatty acid), mimicking the nutrient 
microenvironment of pancreatic b-cells in obese and overweight individuals. It has been 
shown that excess nutrients induce GLT characterized by increased basal insulin secretion 
(2 mM glucose) and decreased GSIS (8 mM glucose) (Saadeh et al. 2012). It has also been 
shown that chronic exposure to excess nutrients leads to a left-shift in GSIS in INS-1 cells 
characterized by secretion of insulin at inappropriately low glucose concentrations (3 to 5 
mM glucose) (Erion et al. 2015). Therefore, in our secretion experiments we chose to 
measure insulin secretion at 2, 4 and 8 mM glucose concentrations in INS-1 cells to assess 
INS-1 cell function in response to excess nutrients.  
 To induce GLT in INS-1 cells, we raised the glucose concentration of INS-1 cells 
chronically cultured in 4 mM to 11 mM plus 0.1 mM oleate and maintained this condition 
for 48 hours. After 48 hours, intracellular lipid (Figure 10), insulin secretion (Figures 11 
and 13) and insulin content (Figure 12) were measured.  
Since increased intracellular lipid droplets are characteristic of GLT, we imaged 
cells cultured under low glucose and excess nutrient conditions after lipid staining with 
Nile red (Figure 10). INS-1 cells cultured under excess nutrients (panel B) exhibited 
increased appearance of stored lipid droplets inside the cells seen as large bright green dots 
when compared to the low glucose control condition (panel A). Accumulation of 
intracellular lipid droplets is an indicator of increased cellular lipids and validates that INS-
1 cells cultured in excess nutrients exhibit GLT characteristics.  
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After 48 hours in excess nutrients INS-1 cells exhibited characteristics of GLT 
(Figure 11). Basal (2 mM glucose) insulin secretion from cells chronically cultured in 4 
mM glucose (blue bars) was 7.4 ng/106 cells.  When glucose was acutely raised from 2 mM 
to 4 mM insulin secretion was relatively unchanged (66% increase) compared to the 9-fold 
increase in secretion when glucose was raised from 2 mM to 8 mM. Cells cultured in 11 
mM glucose plus 0.1 mM oleate for 48 hours (red bars) showed increased basal secretion. 
This increase in basal secretion was observed at both 2 and 4 mM glucose concentrations. 
Basal secretion at 2 mM glucose was increased by 90% to 14 ng/106 cells and when glucose 
was acutely raised to 4 mM, secretion was increased 110% (14 to 29.6 ng/106 cells). This 
increase represents a left shift in GSIS compared to cells cultured under low glucose 
conditions (Erion et al. 2015).   
Stimulated insulin secretion at 8 mM glucose was reduced 43% from 68 to 39 
ng/106 cells in cells exposed to excess nutrients. The fold increase in GSIS from cells 
cultured in low glucose compared to cells exposed to excess nutrients was reduced from 
9.3 to 2.8-fold compared with cells grown in 4 mM glucose.  
Insulin content of cells treated with excess nutrients dropped by half from 2193 
ng/106 cells to 1042 ng/106 cells compared to cells cultured in low glucose (Figure 12). 
Since insulin content can affects insulin secretion we corrected the expression of insulin 
secretion in Figure 11 for insulin content measured from the same cells. This is often 
thought to be a measure of insulin exocytosis (Lamontagne et al. 2017). The resulting 
corrected insulin secretion is plotted in Figure 13. When corrected for content the 
differences in secretion at 2 and 4 mM glucose in cells exposed to excess nutrients (red 
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bars) is amplified compared to cells cultured at low glucose (blue bars). This increase in 
basal secretion at both 2 and 4 mM glucose clearly demonstrated that cells exposed to 
excess nutrients hypersecrete insulin and their insulin release is left-shifted compared to 
cells cultured at low glucose. Interestingly, 8 mM glucose-induced insulin secretion, which 
was reduced by exposure to excess nutrients, when corrected for content showed no 
difference compared to the low glucose control (Figure 13). Thus, the increased insulin 
secretion at 2 and 4 mM glucose represented an increase in insulin exocytosis. Insulin 
exocytosis at 8 mM glucose was not different between cells cultured with excess nutrient 
conditions compared to the low glucose control. 
These results clearly demonstrated an early stage of glucolipotoxic INS-1 cells 
characterized by increased basal secretion and stored lipid droplets.  We were next 
interested to see if only raising glucose concentration chronically would exhibit these same 
glucolipotoxic characteristics.   
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Figure 10. Incubation of INS-1 cells in high glucose and fatty acid increased lipid 
accumulation.  
Excess nutrients induced GLT in INS-1 cells by increasing the lipid stored after 48 hours. Nile red 
dye staining of INS-1 cells was used to assess the stored and a representative image taken at 20X 
magnification is shown in panel (A) 4G and panel (B) 11G with 0.1 mM oleate (FA). Similar results 
were obtained in four other such experiments and the images above represents results from an 
independent experiment 
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Figure 11. Insulin secretion of INS-1 cells in high glucose and fatty acid. 
Incubation of INS-1 cells in excess nutrients (high glucose and fatty acid) for 48 hours induced 
GLT characterized by increased basal insulin secretion (blue bar) and decreased GSIS (red bar). 
INS-1 cells were cultured in 4 mM glucose or 11 mM glucose with 0.1 mM oleate (FA) for 48 
hours. These cells were then acutely stimulated with 2, 4 and 8 mM glucose and insulin was 
measured. Similar results were obtained in four other such experiments and the graph above 
represents an independent experiment with three to four replicates averaged and plotted as a mean 
± S.E.M. 
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Figure 12. Insulin content of INS-1 cells in high glucose and fatty acid.  
Insulin content is reduced in INS-1 cells cultured in 11 mM glucose plus 0.1 mM oleate 
compared to normal physiological glucose (4 mM). Similar results were obtained in four other 
such experiments and the graph above represents content from an independent experiment with 
two replicates averaged and plotted as a mean ± S.E.M. 
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Figure 13. Corrected secretion for content from Figure 11. 
Incubation of INS-1 cells in excess nutrients (high glucose and fatty acid) induced GLT 
characterized by decreasing insulin content and therefore left-shifted the dose-response curve of 
GSIS. Insulin secretion was normalized to the total insulin content and expressed as a percentage 
of insulin secretion. Similar results were obtained in four other such experiments and the graph 
above represents an independent experiment with three to four replicates averaged and plotted as 
a mean ± S.E.M. 
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Insulin secretion by INS-1 cells cultured in 11 mM glucose  
INS-1 cells cultured in high glucose and fatty acid for 48 hours exhibited early GLT 
characteristics. Previous studies in our laboratory have demonstrated that incubation of 
INS-1 cells in high glucose alone induces GLT characteristics only after 3 days (Erion et 
al. 2015). To confirm this, we raised the glucose concentration of INS-1 cells chronically 
cultured in 5 mM glucose to 11 mM glucose for 72 hours. After 72 hours intracellular lipid, 
insulin secretion and content were measured.  
Lipid staining of INS-1 cells cultured at high glucose concentration showed 
increased stored intracellular lipid droplets when compared to the low glucose control 
condition (Figure 14A). Accumulation of intracellular lipid inside the cells cultured at high 
glucose validated high glucose alone can induce characteristics of GLT.   
Basal insulin secretion at 2 mM glucose from cells chronically cultured in 5 mM 
glucose (blue bars) was 28.5 ng/106 cells (Figure 15). When glucose was acutely raised 
from 2 mM to 4 mM insulin secretion was relatively unchanged compared to the 3.7-fold 
increase in secretion when glucose was raised from 2 mM to 8 mM. Basal insulin secretion 
at 2 mM glucose from cells cultured in 11 mM glucose (red bars) was 23.2 ng/106 cells. 
When glucose was acutely raised to 4 mM, secretion increased 95% (23.2 to 45.3 ng/106 
cells). This increase validated the left-shift in GSIS compared to cells cultured under low 
glucose conditions (Erion et al. 2015). 
GSIS (8 mM) was reduced 41% from 105 to 62.4 ng/106 cells in cells exposed to 
excess nutrients compared to low glucose conditions. The fold increase in GSIS from cells 
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cultured in low glucose compared to cells exposed to excess nutrients was reduced from 
3.7 to 2.7-fold.  
Insulin content of the cells cultured with high glucose concentration compare to 
cells cultured in low glucose dropped by 5.7-fold from 6981 ng/106 cells to 1227 ng/106 
cells (Figure 16A). Insulin secretion from Figure 15 is plotted as percent content in Figure 
16B. When corrected for content the differences in secretion at 2 and 4 mM glucose in cells 
exposed to excess nutrients (red bars) was amplified compared to cells cultured at low 
glucose (blue bars). This increase in basal secretion at both 2 and 4 mM glucose, clearly 
demonstrates that cells exposed to excess nutrients (high glucose alone) hypersecrete 
insulin and insulin release is left-shifted compared to cells cultured at low glucose. 
Interestingly, 8 mM glucose-induced insulin secretion, which was reduced in Figure 15 
due to high glucose, when corrected for content showed increased insulin secretion 
compared to the low glucose control (Figure 16B). Increased insulin secretion at 2, 4 and 
8 mM glucose would represent an increase in insulin exocytosis at each glucose 
concentration.  
These results clearly demonstrated that incubation of INS-1 cells in high glucose 
alone induces GLT characteristics by increased basal and a left-shift in GSIS in addition to 
accumulation of stored lipids. Since GLT characteristics in INS-1 cells can be 
accomplished in our experiments by only raising glucose concentration to 11 mM in the 
regular media we decided to use cells cultured at high glucose as our model for GLT in our 
following experiments.  
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Figure 14. Incubation of INS-1 cells in high glucose increased lipid accumulation. 
Incubation of INS-1 cells under 11 mM glucose (B) for 72 hours induced GLT characterized by 
increasing the lipid stored in this INS-1 cells). Nile red dye staining of INS-1 cells was used to 
assess the lipid stored and some representative images taken at 20X magnification are shown for 
INS-1 cells grown in 5 mM and 11 mM glucose. Similar results were obtained in four other such 
experiments and the images above represents results from an independent experiment.  
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Figure 15. Insulin secretion of INS-1 cells in high glucose.  
Incubation of INS-1 cells in high glucose induced GLT characteristics by increased basal insulin 
secretion (blue bar), a left-shift in GSIS (blue bar at 4 mM glucose) and decreased GSIS (red bar 
at 8 mM glucose). INS-1 cells were cultured in 5 mM glucose or 11 mM glucose for 72 hours. 
These cells were then acutely stimulated with 2, 4 and 8 mM glucose and insulin were measured. 
Similar results were obtained in four other such experiments and the graph above represents an 
independent experiment with three to four replicates averaged and plotted as a mean ± S.E.M. 
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Figure 16. Insulin content(A), and corrected secretion for content form Figure 15 (B).  
Incubation of INS-1 cells in excess nutrients (high glucose alone) induced GLT characterized by 
decreased insulin content (A) and therefore left-shifted the dose-response curve of GSIS. Similar 
results were obtained in four other such experiments and the graphs above represents an 
independent experiment with three to four replicates for secretion graph (B) and two replicates for 
content graph (A) averaged and plotted as a mean ± S.E.M.  
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Insulin secretion of INS-1 cells cultured in 5 mM glucose in the presence of AhR 
ligands  
 Since it is known that fatty acids and fatty acid derivatives activate AhR (McMillan 
and Bradfield 2007), we were then interested to examine the potential role of AhR in 
mediating GLT in the b-cells.  To do this we measured insulin secretion from INS-1 cells 
after exposure to AhR antagonist or agonist to inhibit or activate the AhR respectively. In 
previous studies different concentrations of these ligands of AhR were used to activate or 
inhibit its activity. To determine the optimal effective dose of AhR ligands used in INS-1 
cells, we treated cells grown in low glucose with AhR agonist (FICZ) and antagonist 
(CH223191) at concentrations of 0, 1.25, 5 and 10 μM for 3 days. After three days of 
treatment, insulin secretion was measured.   
Basal insulin secretion from INS-1 cells cultured in 5 mM glucose was mostly 
unaffected by the antagonist after three days at the concentrations used in this experiment. 
However, treatment with antagonist for three days caused a dose-dependent increase in 
GSIS (37 to 54 ng/106cells) (Figure 17A).  
Agonist treatment for three days resulted in a dose dependent increase in basal 
section (5 to 13 ng/106cells) and a dose dependent decrease (23 to 15 ng/106cells) in GSIS 
(Figure 17B). 
 Preliminary results shown in figure 17 provide evidence that the AhR antagonist 
improves GSIS while the AhR agonist impairs GSIS from INS-1 cells cultured under low 
glucose conditions.  The most effective concentration tested that impacted insulin secretion 
from INS-1 cells for both antagonist and agonist was 10 µM.  
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Figure 17. Insulin secretion by INS-1 cells cultured in 5mM glucose under AhR agonist (B) 
and antagonist (A). Antagonist dose-dependently increased while agonist dose-dependently 
decreased GSIS in INS-1 cells cultured in low glucose. INS-1 cells were cultured in 5 mM glucose 
in indicated doses of antagonist for 72 hours. These cells were then acutely stimulated with 2 and 
8 mM glucose and insulin was measured. Similar results were obtained in three other such 
experiments and the graphs above represents an independent experiment with three to four 
replicates averaged and plotted as a mean ± S.E.M. 
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Toxicity of AhR ligands to INS-1 cells cultured in 5 and 11 mM glucose 
 To show that the concentrations of AhR ligands used had no adverse effect on cell 
viability, INS-1 cells cultured in low glucose and high glucose were treated with 2.5 and 
10 µM concentrations of agonist and antagonist for four days (Figure 18). When INS-1 
cells chronically cultured in 5 mM glucose were used, the glucose concentration was also 
raised to 7 mM. When INS-1 cells chronically cultured in 11 mM glucose were used, the 
glucose concentration was also lowered to 7 mM.  After four days, cell numbers were 
counted for each condition.  
Although the starting glucose concentration had some effect on cell number after 4 
days culture (7 vs 11 mM glucose in Figure 18A), the cell number was unaffected by either 
antagonist or agonist at the concentrations tested. Therefore, AhR agonist or antagonist at 
the concentrations used in this study showed no toxicity as measured by cell proliferation.  
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Figure 18. Cell viability of INS-1 cells cultured in 5 or 11mM glucose and AhR ligands.  
INS-1 cell number per 96 well plate cultured in 11 mM glucose (red bar) or 7 mM glucose (green 
bar) in the presence of different concentrations of antagonist (A). INS-1 cell number per 96 well 
plate of cells grown in 5 mM glucose (Blue bar) or 7 mM glucose (green bar) in the presence of 
different concentration of agonist (B). These cell numbers were then counted with 
hemocytometer. Results are pooled data from five or six independent experiments (n=4 
replicates) averaged and plotted as a mean ± S.E.M. p£0.05 is significant (One-way ANOVA 
results are 11G vs 7G cell number with a p= 0.006). 
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Effect of AhR antagonist on lipid accumulation in INS-1 cells  
INS-1 cells were cultured in 11 mM glucose with 0, 1.25, 2.5, 5 and 10 µM 
concentrations of antagonist for four days. In addition, glucose concentration of these cells 
was lowered to 8 mM and 5 mM and incubated with the same antagonist concentrations. 
After four days cells were stained with Nile red and images were taken and analyzed using 
ImageJ software as described in methods. Figure 19A shows images of Nile red stained 
INS-1 cells cultured at 11 mM glucose with 0, 2.5 and 10 µM antagonist. The quantitation 
of lipid droplet area as a percent of total area of INS-1 cells from these images as well as 
others taken from cells cultured at lower glucose concentrations is shown in Figure 19B. 
When glucose was lowered from 11 mM to 8 mM and 5 mM, lipid droplets were 
reduced by approximately 75% and greater than 95% respectively. This is consistent with 
our previous results (Figures 14). The highest antagonist concentration (10 µM) lowered 
the % lipid droplets in INS-1 cells cultured at all glucose concentrations. The lowest 
antagonist concentration (1.25 µM) effectively reduced lipid droplets in cells cultured at 8 
mM glucose while not reducing lipid at 11 mM glucose, which started at a much higher 
concentration of intracellular lipid.  
 
 
 
 
 
 
 43 
 
 
 
Figure 19. AhR antagonist effect on lipid accumulation in INS-1 cells. 
Antagonist dose dependently decreased lipid accumulation in INS-1 cells. (B) ImageJ analysis of 
Nile red pictures in (A). Greatest effect of antagonist in decreasing intracellular lipid was observed 
in cells grown in 11 mM glucose shown in panel A. Nile red images of intracellular lipid droplets 
of 11 mM glucose cells in 2.5 µM and 10 µM antagonist concentrations (A). INS-1 cells were 
cultured in 11 mM glucose or switched from 11 to 8 mM or 5 mM glucose and antagonist was 
added at 1.25, 2.5, 5 or 10 µM final cell concentration for 96 hours. Similar results were obtained 
in three other such experiments and the images in panel A and image analysis in panel B represents 
results from an independent experiment. Image analysis data was averaged and plotted as a mean 
± S.E.M.  
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Effect of AhR antagonist on insulin secretion and content from INS-1 cells 
INS-1 cells were cultured in 11 mM glucose with 0, 2.5 and 10 µM concentrations 
of antagonist for four days. In addition, glucose concentration of these cells was lowered 
to 7 mM and incubated with the same antagonist concentrations. After four days insulin 
secretion and content were measured.  
Basal insulin secretion at 2 mM glucose from cells chronically cultured in 11 mM 
glucose (red solid bar) was 14.19 ng/106 cells and did not change as the antagonist dose 
increased (Figure 20A). When glucose was acutely raised from 2 mM to 4 mM insulin 
secretion increased by 75% (red solid bar) in these cells, while in the presence of 2.5 µM 
and 10 µM antagonist dose, it increased by 30% (red dotted bar) and 46% (red striped bar) 
respectively.  Insulin secretion increased 3-fold in the absence of antagonist (red solid bar), 
when glucose was raised from 2 mM to 8 mM, 3.7-fold when cultured with 2.5 µM 
antagonist (red dotted bar) and 4.3-fold when cultured with 10 µM antagonist (red striped 
bar). These changes were significant when analyzed using two-way ANOVA with glucose 
and antagonist concentrations as independent variables.   
Basal insulin secretion at 2 mM glucose from cells chronically cultured in 11 mM 
and switched to 7 mM for four days (green solid bar) was 26.2 ng/106 cells and did not 
change as the antagonist dose increased (Figure 20B). When glucose was acutely raised 
from 2 mM to 4 mM insulin secretion increased by 53% (green solid bar) in these cells, 
while in the presence of 2.5 µM and 10 µM antagonist, it increased by 76% (green dotted 
bar) and 130% (green striped bar) respectively.  Insulin secretion increased 3-fold when 
glucose was raised from 2 mM to 8 mM in the absence of antagonist (green solid bar), 3.2-
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fold when cultured with 2.5 µM antagonist (green dotted bar) and 4.5-fold when cultured 
with 10 µM antagonist (green striped bar). These changes when analyzed using two-way 
ANOVA with glucose and antagonist concentrations as independent variables were 
significant. 
These results clearly demonstrate that the antagonist dose-dependently increases 
both basal insulin secretion and GSIS. To determine whether these antagonist-induced 
changes in secretion were due to an effect on exocytosis we again measured insulin content. 
INS-1 cells cultured in 11 mM glucose had 868 ng/106 cells content, which is 
typical for cells exhibiting GLT characteristics. Content in cells cultured in 11 mM glucose 
with antagonist was significantly increased at both 2.5 µM (1049 ng/106 cells) and 10 µM 
(1278 ng/106 cells). This represented a 2.6-fold and 2.9-fold increase in content 
respectively (Figure 21).  
When the glucose was lowered from 11 mM to 7 mM, the content increased to 2047 
ng/106 cells, which is typical of  cells cultured at lower glucose concentration. When 
glucose was lowered to 7 mM and was combined with 2.5 µM or 10µM antagonist 
treatment, insulin content was increased by 10% and 20% (1.1 and 1.2-fold) respectively 
(Figure 21).  
Insulin secretion from Figure 20 A and B was plotted as percent content in Figure 
22 A and B. When corrected for content the antagonist dependent increase in insulin 
secretion at 4 and 8 mM glucose was abolished. Therefore, we can conclude that the 
improvement in insulin secretion mediated by antagonist treatment was due to increased 
insulin content rather than a direct effect on exocytosis.  
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These results clearly demonstrated that under excess nutrients the AhR antagonist 
decreased lipid accumulation, increased insulin secretion and content in INS-1 cells.  Since 
the antagonist was shown to improve secretion from INS-1 cells, we were then interested 
to determine the effects of AhR agonist on lipid accumulation from these cells.  
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Figure 20. Effect of AhR antagonist on insulin secretion from INS-1 cells.  
INS-1 cells were cultured in 11 mM glucose (A)(red bars) or switched from 11 to 7 mM (B)(green 
bar) glucose in the presence of 2.5 or 10 µM antagonist for 96 hours. Results are pooled data from 
three independent experiments (n=4 replicates) averaged and plotted as a mean ± S.E.M. p£0.05 is 
significant. (Two-way ANOVA results are 11G (A); Glucose dose effect p= 6.6 X 10-14, drug dose 
effect p=2.9 X 10-5 , glucose dose effect vs drug dose effect p= 0.003,  7G (B); Glucose dose effect 
p= 2.5 X 10-9, drug dose effect p= 0.003 , glucose dose effect vs drug dose  effect p= 0.07) 
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Figure 21. Effect of AhR antagonist on insulin content from INS-1 cells. 
Insulin content is increased dose dependently in INS-1 cells cultured in 11 mM glucose (red bar) 
or switched to 7 mM glucose (green bar) in the presence of antagonist. INS-1 cells were cultured 
in 11 mM glucose or switched from 11 to 7 mM glucose in the presence of 2.5 or 10 µM 
concentrations of antagonist for 96 hours. Results are pooled data from three independent 
experiments (n=4 replicates) averaged and plotted as a mean ± S.E.M. p£0.05 is significant. (One-
way ANOVA results are 11G (red bars); drug dose effect p=0.03. 7G (green bars); drug dose effect 
p=0.11).  
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Figure 22. Insulin secretion from Figure 20 corrected for insulin content. 
INS-1 cells were cultured in 11 mM glucose (A)(red bars) or switched from 11 to 7 mM (B)(green 
bar) glucose in the presence of 2.5 or 10 µM antagonist for 96 hours. Results are pooled data from 
three independent experiments (n=4 replicates) averaged and plotted as a mean ± S.E.M. p£<0.05 
is significant. (Two-way ANOVA results are 11G(A) ; Glucose dose effect p= 1.7 X 10-10 , drug 
dose effect p = 0.7, glucose dose effect vs drug dose effect p= 0.9, 7G (B); Glucose dose effect p= 
1.4 X 10-8, drug dose effect p= 0.2 ,glucose dose effect vs drug dose effect p= 0.5).  
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Effect of AhR agonist on lipid accumulation in INS-1 cells  
INS-1 cells were cultured in 5 mM glucose with 0, 1.25, 2.5, 5 and 10 µM 
concentrations of agonist for four days. In addition, the glucose concentration of these cells 
was raised to 8 mM and 11 mM and incubated with the same agonist concentrations. After 
four days cells were stained with Nile red and images were taken and analyzed using 
ImageJ software as described in methods. Figure 23A shows images of Nile red stained 
INS-1 cells cultured at 5 mM glucose with 0, 2.5 and 10 µM agonist. The quantitation of 
lipid droplet area as a percent of total area of INS-1 cells from these images as well as 
others taken from cells cultured at lower glucose concentrations is shown in Figure 23B. 
When glucose was raised from 5 mM to 8 mM and 11 mM, lipid droplets were 
increased from approximately 0.02% to 0.5% and 0.8% respectively. This was consistent 
with our previous results (Figures 14). The lowest agonist concentration (1.25 µM) had the 
most dramatic effect on cells cultured in 11 mM glucose which already had the highest 
lipid accumulation of the three glucose concentrations tested. The highest agonist 
concentration (10 µM) increased the percent lipid droplets in INS-1 cells cultured at all 
glucose concentrations. Fold increase in percent lipid accumulation was 170, 7 and 9 for 
cells cultured in 5 mM, 8 mM and 11 mM glucose respectively.  
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Figure 23. AhR agonist effect on lipid accumulation in INS-1 cells. 
Agonist (FICZ) dose dependently increased lipid accumulation in INS-1 cells. ((B) ImageJ analysis 
of Nile red stains in (A). Highest effect of agonist in increasing lipid accumulation is in cells grown 
in 5mM glucose. (A) Nile red images of intracellular lipid droplets of cells grown in 5 mM glucose 
in the presence of 2.5 µM and 10 µM agonist (B). INS-1 cells were cultured in 5 mM glucose or 
switched from 5 to 8 mM or 11 mM glucose and agonist was added at 1.25, 2.5, 5 or 10 µM 
concentrations for 96 hours. Similar results were obtained in three other such experiments and the 
images in panel A and image analysis in panel B represents results from an independent experiment. 
Image analysis data was averaged and plotted as a mean ± S.E.M.  
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Effect of AhR agonist on insulin secretion and content from INS-1 cells 
 INS-1 cells were cultured in 5 mM glucose with 0, 2.5 and 10 µM concentrations 
of agonist for four days. After four days insulin secretion and content were measured. Basal 
insulin secretion at 2 mM glucose from cells chronically cultured in 5 mM glucose was 
10.6 ng/106 cells (blue solid bar). 2.5 and 10 µM agonist increased basal insulin secretion 
by 32 and 37 % respectively (Figure 24). When glucose was acutely raised from 2 mM to 
4 mM insulin secretion did not increase under any of the conditions. When glucose was 
raised from 2 mM to 8 mM insulin secretion increased 2.5-fold in the absence of agonist 
(blue solid bar), 1.9-fold when cultured with 2.5 µM agonist (blue dotted bar) and 2.1-fold 
when cultured with 10 µM agonist (blue striped bar). 
These results demonstrate that the agonist increases basal insulin secretion. To 
determine whether these agonist-induced changes in secretion were due to an effect on 
exocytosis we again measured insulin content. 
INS-1 cells cultured in 5 mM glucose had 628 ng/106 cells content, which is typical 
for cells exhibiting GLT characteristics. Content in cells cultured in 5 mM glucose with 
agonist was significantly decreased at both 2.5 µM (572 ng/106 cells) and 10 µM (383 
ng/106 cells).  This represents a 9% and 40% decrease in content respectively (Figure 25A).   
Insulin secretion from Figure 24 is plotted as percent content in Figure 25 panel B. 
When corrected for content the agonist dependent increase in insulin secretion at 2 and 4 
mM glucose was amplified and exhibited a dose-dependency.  
This increase in basal secretion at both 2 and 4 mM glucose, demonstrates that cells 
exposed to agonist hypersecrete insulin compared to control cells. Interestingly, 8 mM 
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glucose-induced insulin secretion, which was unchanged in Figure 24 across all doses, 
when corrected for content showed a 75% increase in cells treated with 10 µM agonist 
(blue striped bar) compare to control cells (blue solid bar). Therefore, we can conclude that 
the increase in basal insulin secretion mediated by agonist treatment is not due to decreased 
insulin content but rather a direct effect on exocytosis.  
These results demonstrated that the AhR agonist increased lipid accumulation, 
increased basal insulin secretion and decreased content in INS-1 cells, which represent 
three of the four GLT characteristics.   
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Figure 24. Effect of AhR agonist on insulin secretion from INS-1 cells.  
Agonist treatment of INS-1 cells grown in 5 mM glucose resulted in increased basal 
secretion.Insulin secretion of INS-1 cells grown in 5mM glucose after 96 hours of agonist 
treatment. INS-1 cells were cultured in 5 mM glucose in the presence of 2.5 or 10 µM of agonist 
for 96 hours. Resulting graph is a single independent experiment. The bars are representative of 
four replicates that are averaged and plotted as a mean ± S.E.M. 
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Figure 25. Insulin content (A) and corrected secretion for content form Figure 24(B).  
Insulin content (A) and secretion in figure 24 corrected for content (B) of INS-1 cells cultured in 5 
mM glucose (blue bar) in the presence of agonist. INS-1 cells were cultured in 5 mM glucose in 
the presence of 2.5 or 10 µM concentrations of agonist in the media for 96 hours. Resulting graph 
is a single independent experiment. The bars are replicates of four replicates in panel B and two 
replicates in panel A that are averaged and plotted as a mean ±S.E.M.  
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DISCUSSION 
 
The role of b-cell function in the pathogenesis of T2D is not completely understood. 
It is generally excepted that high fat and glucose (excess nutrients) induce GLT and lead 
to pancreatic beta cell dysfunction over time. This study provides evidence suggesting that 
the AhR may partly mediate the effects of excess nutrients to impair b-cell function. 
Inhibition of AhR using antagonist CH223191 dose-dependently decreased 
intracellular lipid droplets of INS-1 cells cultured with excess nutrients. This was 
accompanied by a dose-dependent increase in insulin content and increased insulin 
secretion.  Increased secretion was a result of increased content rather than an effect of the 
antagonist to increase exocytosis.  
In contrast, activation of AhR by agonist FICZ dose-dependently increased 
intracellular lipid droplets and decreased insulin content in INS-1 cells cultured in low 
glucose conditions. This resulted in increased insulin secretion when corrected for content 
indicating an effect of the agonist to increase exocytosis in INS-1 cells. These important 
results provide the evidence that aryl-hydrocarbon receptor could potentially play a 
mediatory role in the developmental of GLT. 
Prior to studying the effect of AhR on b-cell function we first set out to establish a 
model of GLT in INS-1 cells. GLT is characterized by an increase secretion at basal (2 mM 
glucose) concentration and decreased GSIS. More recently we have published that GLT 
increased intracellular lipid droplets and decreased insulin content in INS-1 cells (Figure 
3) (Erion et al. 2015). In addition, cells cultured with excess nutrients are left shifted in 
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their glucose response compared to cells cultured at more physiological glucose levels 
(Erion et al. 2015). Our model of GLT established in this study by the addition of high fat 
and glucose concentration in the media exhibited all of these characteristics (Figures 10 
and 13). When only the glucose concentration of the media was raised, the GLT 
characteristics were not as severe compared to when glucose and fat concertation were both 
raised. The reason why INS-1 cells in high glucose alone exhibited GLT characteristics is 
that FBS already contains lipid (FA and TG). These results demonstrate that the GLT can 
increase intracellular lipid in INS-1 cells exposed to excess nutrients in culture. Previous 
findings from our lab clearly demonstrated the linear inverse relationship between 
intracellular lipid and secretion from INS-1 cells (Figure 4).  
In the amplification pathway of insulin secretion, LC-CoA or other additional 
effectors play a major role in further stimulating insulin secretion (Figure 2). Antagonist 
activity on AhR resulted in depletion of intracellular lipid droplets and improvement in 
secretion of INS-1 cells. Inhibition of the AhR potentially initiated a mechanism involved 
in changing intracellular lipid metabolism, possibly reducing FA esterification into TG 
within lipid droplets or increasing triglyceride hydrolysis. It could also be that inhibition 
of AhR increases FA oxidation in the b-cell, although this was not measured. GSIS of INS-
1 cells treated with antagonist was improved and as suggested earlier, the improvement in 
secretion may be due to the reduction in intracellular lipids content.  
The accumulation of lipid inside the cells treated with the AhR agonist FICZ 
suggests that lipid synthesis machinery is activated in these cells. It may also be that FA 
oxidation is decreased by AhR activation, although this was not measured in this study. 
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The fact that the cells accumulated lipid and their secretion is impaired when AhR is 
activated suggests that the cells exhibit glucolipotoxic effects when activating the receptor 
even at low nutritional states.  
Intracellular lipid can be affected by a number of different pathways that may be 
regulated by the AhR. Additionally, it is known that SREBP and Peroxisomal Proliferator-
Activated Receptor (PPAR) g and a are transcription factors important for lipid synthesis 
inside the cells (Williams 2017; Ardestani et al. 2018).  In our collaborating laboratory, 
there was an attempt to measure SREBP activity under excess nutrient since it is known 
that under excess nutrient condition, mTORC1 signaling activity is high and is therefore 
the accumulation of lipid droplets inside the cell (Eid et al. 2017; Bakan and Laplante 2012, 
1; Porstmann et al. 2008). SREBP is located downstream of mTORC1 signaling and it is 
known to be activated by mTORC1 (Lewis et al. 2011, 1; Porstmann et al. 2008; Shimano 
et al. 2007)  It is known that SREBP expression and activity is regulated by diabetes and 
nutritional statues and it has an important role in regulation of lipid and carbohydrate 
metabolism (Horton, Goldstein, and Brown 2002; Walker and Näär 2012; Jeon and 
Osborne 2012; Shao and Espenshade 2012).  
Additionally, it is known that mTORC 1 activity increases PPAR g and inhibits a 
signaling(DM n.d.; Dunlop and Tee 2009; Laplante and Sabatini 2012; Blandino-Rosano 
et al. 2012). AhR by itself is known to activate PPAR a and g in different cell lines or mice 
model (Shaban et al. 2004; Ernst et al. 2014; Wang et al. 2011). It is not known whether 
the PPAR activity is the reason to why INS-1 cells accumulate lipid intracellularly when 
AhR is active and therefore in the future we would like to measure PPAR a and g activity 
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in INS-1 cells.  
 The receptor antagonist reduced the intracellular lipid and improved insulin 
secretion under excess nutrient conditions, suggesting that FA oxidation may have been 
increased in these cells. AMPK activity if increased could result in lower malanyl co-A 
levels and relieve inhibition of FA oxidation under high glucose conditions. To test whether 
AMPK activation level is altered we plan to run western and blot for both phosphorylated 
and total AMPK.  
In summary, the AhR may play a role in the development of GLT in pancreatic  
b-cells cultured in excess nutrients. AhR could be a mediator responsible for lipid 
accumulation in INS-1 cell and further resulting in hypersecretion.  
Further research is needed to validate these effects of activation or inhibition of 
AhR in human pancreatic islets. The relationship obtained in this study between stored 
lipid and hypersecretion of insulin suggests the need to further investigate which lipids are 
mediating these effects.  Lipidomic analysis to characterize and better understand the 
composition of intracellular lipids such as cholesterol, monoacylglycerol (MAG), 
diacylglycerol (DAG) and triglycerides (TG) will help elucidate the mechanisms of basal 
insulin hypersecretion.   
We hope that future research will allow us to better understand AhR activity under 
excess nutrient conditions and its mediatory role in b-cell function. We hope that these 
results are a stepping stone in the development of more targeted therapeutic treatment of 
not only diabetes but also obesity and their complications.  
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